The APPOLO study demonstrated the remarkable efficacy and safety profile of aumolertinib in patients with EGFR T790M-positive NSCLC, showcasing its effectiveness, particularly in brain metastases (BM) (13). This evidence concerns the gene EGFR and non-small cell lung carcinoma.